- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 20
- States / cities
- Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 280
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Arthritis, Rheumatoid
- Interventions
- LY3009104, Placebo, Methotrexate
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 31
- States / cities
- Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more
- Conditions
- Respiratory Syncytial Virus Infections, Virus Diseases
- Interventions
- JNJ-53718678, Placebo
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 1 Month to 24 Months
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Kirksville, Missouri
- Conditions
- Nicotine Dependence
- Interventions
- Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing
- Device · Drug · Behavioral
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy Volunteer
- Interventions
- ABBV-142, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois
- Conditions
- Multiple Sclerosis
- Interventions
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
- Drug
- Lead sponsor
- Synthon BV
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 794 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
- Conditions
- Smoking Cessation
- Interventions
- SBP-9330, Placebo
- Drug
- Lead sponsor
- Camino Pharma, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Cardiovascular Diseases, Heart Diseases, Obesity
- Interventions
- Sibutramine, Behavioral Smoking Cessation Program
- Drug · Behavioral
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Alzheimer's Disease
- Interventions
- TB006, Placebo
- Drug
- Lead sponsor
- TrueBinding, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 18
- States / cities
- Garden Grove, California • San Diego, California • Delray Beach, Florida + 10 more
- Conditions
- Delayed Graft Function
- Interventions
- OPN-305, Placebo
- Drug
- Lead sponsor
- Opsona Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- LY2439821, Placebo
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 37
- States / cities
- Peoria, Arizona • La Mesa, California • Palm Desert, California + 34 more
- Conditions
- Healthy Volunteers
- Interventions
- KarXT, KarX-EC, Placebo, Omeprazole
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Resistant Hypertension
- Interventions
- Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 41
- States / cities
- Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
- Conditions
- Healthy Volunteer
- Interventions
- ABBV-CLS-616, Placebo, Itraconazole
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois
- Conditions
- Diabetes
- Interventions
- BMS-903452, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Miramar, Florida • Austin, Texas
- Conditions
- Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
- Interventions
- Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
- Drug · Diagnostic Test · Dietary Supplement
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Volunteer
- Interventions
- ABBV-701, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Anaheim, California • Grayslake, Illinois
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
- Interventions
- Inhaled Nitric Oxide
- Drug
- Lead sponsor
- Geno LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo, Survodutide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 80 more
- Conditions
- Kidney Disease, Chronic
- Interventions
- BI 690517, Placebo matching BI 690517, Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Huntsville, Alabama • Surprise, Arizona • Beverly Hills, California + 46 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Axitinib (AG-013736), Best Supportive Care, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 13
- States / cities
- Berkeley, California • La Jolla, California • Orange, California + 7 more
- Conditions
- Dravet Syndrome
- Interventions
- ZX008 (Fenfluramine Hydrochloride), Matching Placebo
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
- Conditions
- Dyslipidaemias, Heart Failure
- Interventions
- GW510516X
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania